secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPACT BIOMEDICAL INC. (IBO)
CIK:        0001834105
Form:       8-K
Filed at:   2026-09-14T23:43:54+00:00
Accession:  0001493152-26-042635
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Impact Biomedical corrects merger ratio to 1:1, sets 1-for-12.62 reverse split effective Sept 23
--------------------------------------------------------------------------------

- Reverse stock split 1-for-12.62 effective Sept 23, 2026; shares drop from ~107.8M to ~8.5M.
- Corrected merger ratio: 1 Zoar share per 1 Impact share after split, replacing incorrect 1-for-4 in Sept 11 release.
- Stockholders authorized split Dec 30, 2025 within 1-for-12.48 to 1-for-50 range; CEO fixed ratio at 12.62.
- Split aims to support Zoar merger and regain NYSE American continued-listing compliance; no assurance of success.
- Transfer agent Equiniti manages exchange; fractional shares rounded up; new CUSIP for IBO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1834105/000149315226042635/0001493152-26-042635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1834105/000149315226042635/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-042635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer